Akari Therapeutics (CLA1) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nomacopan (Rva576) | Bullous Pemphigoid | Phase III | Withdrawn | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Sep 15, 2021 | ― |
| Nomacopan (Rva576) | Thrombotic Microangiopathies | Phase III | Terminated | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Nov 19, 2020 | ― |
| Rva576 | Bullous Pemphigoid (Bp) | Phase II | Completed | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Apr 12, 2019 | ― |
| Rva576 | Conjunctivitis, Allergic, Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | phase1AndPhase2 | Terminated | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis | Feb 13, 2019 | ― |
| Rva576 | Paroxysmal Nocturnal Hemoglobinuria | Phase III | Terminated | rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Dec 20, 2018 | ― |
| Standard Of Care (Soc), Rva576 | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Phase III | Completed | Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 | Jun 01, 2018 | ― |
| Coversin | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Phase II | Completed | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms | Jan 24, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nomacopan (Rva576) | Phase III | Bullous Pemphigoid | Withdrawn | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Sep 15, 2021 | ― |
| Nomacopan (Rva576) | Phase III | Thrombotic Microangiopathies | Terminated | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Nov 19, 2020 | ― |
| Rva576 | Phase II | Bullous Pemphigoid (Bp) | Completed | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Apr 12, 2019 | ― |
| Rva576 | phase1AndPhase2 | Conjunctivitis, Allergic, Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | Terminated | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis | Feb 13, 2019 | ― |
| Rva576 | Phase III | Paroxysmal Nocturnal Hemoglobinuria | Terminated | rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Dec 20, 2018 | ― |
| Standard Of Care (Soc), Rva576 | Phase III | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Completed | Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 | Jun 01, 2018 | ― |
| Coversin | Phase II | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Completed | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms | Jan 24, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Akari Therapeutics PLC (ADR) (DE:CLA1) have in its pipeline
Akari Therapeutics DE:CLA1 is currently developing the following drugs: Nomacopan (Rva576), Rva576, Standard Of Care (Soc), Rva576, Coversin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.